Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
For patients having a procedure to open severe blockages in the heart's arteries. Due to your severe blockages and weakened heart function, you may be at higher risk of having a drop in blood flow. THE MAGENTA ELEVATE device heart pump device is used during the procedure. This device is intended to prevent drops in blood flow during the procedure. It does this by assisting the heart in pumping blood through the body.
Heart function less than 50%. Participant signed the informed consent. Additional criteria will be assessed prior to enrollment.
Exclusion Criteria:
You may not participate IF: 1. Age less than 18 and greater than 89 years old. 2. Cardiac arrest or Cardiogenic shock 3. Prior stroke or TIA within 3 months prior to enrollment. 4. Participant is presently or has recently been intubated. Additional criteria will be assessed prior to enrollment.
Interventions:Drug/Device: The Magenta Elevate? System
A new study called COMET-HF (sponsored by Cytokinetics, Inc.) is looking to see whether a study medicine called omecamtiv mecarbil can lower the risk for heart failure-related events and deaths, heart transplant, and strokes in people who have heart failure with a low ejection fraction (when the heart isn?t pumping out as much blood as it should with each beat).
This trial enrolls adults (18?85) with long-standing heart failure with a weak heart pumping function who are already on regular water-pill (diuretic) treatment.
They must also have recently gotten sicker from their heart failure ? either currently hospitalized for it, had a qualifying flare-up in the past year, or needed a notable increase in their diuretic medication at home due to worsening symptoms.
The heart function test must be fairly recent and not skewed by a procedure that could have temporarily boosted it.
Exclusion Criteria:
Patients can?t join the study if they:
? Have irregular heartbeat (AFib) and take digoxin
? Had a heart attack, unstable chest pain, or heart surgery/procedures in the last 3 months
? Live in a nursing home or hospice
? Are expected to live less than a year from a non-heart illness (like cancer)
? Recently needed strong IV heart/blood pressure support medications (within 3 days)
Interventions:Drug/Device: OMECAMTIV MECARBIL
Conditions:Heart failure with reduced ejection fraction and established on guidelines directed medical therapy.
This study aims to promote long-term adherence to exercise in adults with heart failure with preserved ejection fraction (HFpEF) by providing an exercise coach for up to one year. We will test a virtual group and in-person group against each other and against virtual enhanced usual care.
This study is looking at whether a home-based exercise program, supported by mobile technology (such as a smartphone app, wearable device, or remote monitoring tools), can help people who have received a HeartMate 3 (HM3) LVAD become more active, stronger, and healthier after surgery.
This study is for adults who have recently received their first HeartMate 3 LVAD, are able to get around independently, have a smartphone, and are living at home (or will be soon after discharge). These requirements help ensure participants can safely take part in the home-based exercise program and use the mobile technology involved in the study.
Exclusion Criteria:
A person cannot take part in the study if they have other serious health problems that would make exercise unsafe or not possible. This includes major movement or nerve problems (like severe joint or brain/nerve conditions), worsening or unstable heart failure, dangerous or poorly controlled heart rhythms, or chest pain caused by reduced blood flow to the heart (unstable angina).
Conditions:Heart Failure
Keywords:Exercise, Heart Failure, Heart Mate III, Heart Pump, HMIII, Left Ventricular Assist Device, LVAD
Heart failure (HF) is a major public health problem that displays wide variation in progression and response to therapy. UPBEAT is a clinical trial pilot study that will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication, a cornerstone of heart failure therapy. Participation requires 8 in-person visits, and randomized assignment to beta-blocker versus placebo medication.
Age 18- 90 years old; Ejection fraction from heart imaging study (EF) of 41-50%; Diagnosis of Heart Failure in hospital, emergency room visit, or through blood work; Expected ability to fully participate in study (can tolerate study processes, no long travel)
Exclusion Criteria:
Specific heart imaging results; Currently on beta blocker heart medication at a higher dose; Not able to take certain heart medications; Unable to complete study activities; Too high or too low heart rate and blood pressure.
This study is testing whether the Aortix System is safe and works better than standard medical treatment for people who are hospitalized with acute heart failure and still have excess fluid buildup (congestion) even after receiving the usual treatments.
The study is looking for adults age 21 and older whose heart failure has recently gotten worse and who still have fluid overload even though standard medications, including diuretics, are not working well enough.
A research study providing new treatment for pulmonary hypertension (high blood pressure in the arteries in the lungs) caused by
left -sided heart disease. This study will evaluate the safety and effectiveness of investigational device called the Multi-Pole Pulmonary Artery Frequency
Ablation Enhancor System ("Enhancor System").
• Subject is diagnosed with left sided heart failure for at least 6 months prior to being evaluated for the study and remains
symptomatic despite an optimal medication regimen as prescribed by their treating physician(s).
• Patient's vital signs and internal heart pressures completed at screening and day of investigational procedure, prior to investigational
implant, meet the study's inclusion requirements.
• . Subject is willing to follow all aspects of the research study, including medication compliance, follow--up visits, and testing.
Exclusion Criteria:
• Subject has a life expectancy of less than 1 year due to non-cardiovascular causes.
• Subject has any severe heart valve disease.
• Subject has had a stroke or mini-stroke within 30 days prior to study enrollment.
• Subject refuses blood products.
• Subject has severe chronic kidney disease or on dialysis
• Subject has severe liver disease
ACT-EARLY is a research study to see if an investigational drug, acoramidis (AG10), is safe and effective in preventing or delaying symptoms of a disease called Transthyretin Amyloidosis (ATTR).This research study will test whether acoramidis treatment in people who do not have the disease but who carry a genetic predisposition to developing the disease is safe and effective in preventing or delaying ATTR disease (genetic predisposition is also referred to as genetic variant).
Carries a specific change (mutation) in the TTR gene that is known, or strongly believed, to cause disease. However, they currently have no signs or symptoms of that disease.
The participant's age must be close to the age when people with their specific TTR gene variant typically start developing symptoms. Specifically, they must be no more than 10 years younger than that expected age. They can be older than the expected age, as long as they are 75 years old or younger.
Exclusion Criteria:
No current stymptoms caused by ATTR amyloidosis.
No current tratment for ATTR amyloidosis
The purpose of this study is to compare outcomes (such as implantable cardioverter-defibrillator (ICD) treatments, hospitalization or death) in participants with heart failure who are treated with carvedilol versus metoprolol succinate
• Patients 18 years of age or older
• Patients with an implantable cardioverter-difibrillator (ICD) implanted for primary prevention for Heart Failure with reduced ejection fraction with remote transmission capability
• Patients currently on treatment with metoprolol succinate and willing to switch to carvedilol
Exclusion Criteria:
• Patients being treated with a beta-blocker (?B) other than metoprolol succinate
• Patients with a known prior intolerance or contraindication to carvedilol
• Patients with a systolic blood pressure <100 mmHg
ACHIEVE-P4: PATHFINDER is a study looking at the impact on symptoms and outcomes of heart failure patients utilizing portable air cleaners in their home. Participants will receive two portable air cleaners and an indoor air quality sensor. The air cleaners will be randomized to either have filters in them or not. Follow-up in-person visits are scheduled at 30- and 90-days after enrollment.
1) Currently in the emergency room or hospitalized with plan to be discharged to home
2) Diagnosis of heart failure
3) Elevated cardiac blood levels
4) Expected ability to fully participate in study (can tolerate study processes, no long travel)
Exclusion Criteria:
Age less than 18 years old; Inability to provide written informed consent; Regular HEPA filter air cleaner use in home already; Current smokers; Has major cardiac procedures within 30 days prior/ 90 days from enrollment
Interventions:Drug/Device: HEPA Portable Air Cleaners
Conditions:Heart Failure
Keywords:Heart Failure, Inpatient, Portable Air Cleaners
